20.03.2020
As part of the immanent advancement of cell-based liquid biopsy, we are happy to announce the filing of the latest patent application of the SanoLibio Project introducing the discovery of new blood circulating rare cell types. We are developing a group of new cellular biomarkers to grade bone marrow damage from the blood mainly for cancer diagnostics. Therefore, our assay is potentially replacing bone marrow biopsy or aspiration for diagnostic purposes. The diagnostic realization operates in the early cancer setting and allows a highly sensitive view into distant invasiveness but more importantly into the agressiveness of an individual tumor. We will be able to correctly stage early phase cancer patients and predict relapsing based on tumor evolution rather than statistics as it currently done by molecular analysis of the primary tumor. We will vastly improve cancer diagnosis impacting therapy decision making and consequently patient outcome and benefit.